Press Release
Akebia Therapeutics Announces Poster Presentations and Educational Symposium at National Kidney Foundation 2021 Virtual Spring Clinical Meetings
Abstracts are now available online in the NKF SCM21 Abstract and ePoster Gallery: https://casehippo.com/spa/symposium/national-kidney-foundation-2021-spring-clinical-meetings/event/gallery/browser.
A poster, titled "A Drug-Drug Interaction Study of Vadadustat Coadministered With Cyclosporine, a P-gp Inhibitor, and Digoxin, a P-gp Substrate" (Poster #171), will present Phase 1 clinical research evaluating the effect of cyclosporine on vadadustat exposure and the effect of vadadustat on the exposure of digoxin (Dig). Vadadustat is Akebia's investigational oral hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI), which recently completed its global Phase 3 clinical development program for the treatment of anemia due to chronic kidney disease (CKD) in adult patients both on dialysis and not on dialysis.
Additional Akebia and Akebia-sponsored posters include:
- Predictors of ESA Use in the Non-Dialysis Dependent Chronic Kidney Disease Population with Anemia (Poster #170)
In addition,
Jeffrey Berns , M.D., who will serve as facilitator and present, "Pathophysiology CKD Anemia and Current Management Strategies;"Volker Haase , M.D., who will present, "Emerging Therapies for CKD Anemia;" and,Stephen Fishbane , M.D., who will present, "Clinical Trials Update: HIF-PHI."
NKF SCM21 attendees can visit the Akebia virtual booth at https://www.akebiavirtualexperience.com/.
About
About Vadadustat
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, which can lead to increased red blood cell production and improved oxygen delivery to tissues. Vadadustat recently completed its global Phase 3 development program for the treatment of anemia due to CKD. Vadadustat is not approved by the
Investor Contact
Ir@akebia.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-announces-poster-presentations-and-educational-symposium-at-national-kidney-foundation-2021-virtual-spring-clinical-meetings-301255231.html
SOURCE
Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142
+1 617.871.2098 phone
+1 617.871.2099 fax